Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016
Published Aug 10, 2016
442 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016, provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)
- The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects
- The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan merger

  
Source:
Document ID
GMDHC8354IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents220
  List of Tables183
  List of Figures211
Introduction221
  Global Markets Direct Report Coverage221
Crohn's Disease (Regional Enteritis) Overview231
Therapeutics Development242
  Pipeline Products for Crohn's Disease (Regional Enteritis) Overview241
  Pipeline Products for Crohn's Disease (Regional Enteritis) Comparative Analysis251
Crohn's Disease (Regional Enteritis) Therapeutics under Development by Companies268
Crohn's Disease (Regional Enteritis) Therapeutics under Investigation by Universities/Institutes341
Crohn's Disease (Regional Enteritis) Pipeline Products Glance354
  Late Stage Products351
  Clinical Stage Products361
  Early Stage Products371
  Unknown Stage Products381
Crohn's Disease (Regional Enteritis) Products under Development by Companies399
Crohn's Disease (Regional Enteritis) Products under Investigation by Universities/Institutes481
Crohn's Disease (Regional Enteritis) Companies Involved in Therapeutics Development4979
  4D Pharma Plc491
  4SC AG501
  AB Science SA511
  AbbVie Inc521
  Alfa Wassermann S.p.A531
  Alteogen Inc.541
  Amgen Inc.551
  Ampio Pharmaceuticals, Inc.561
  ARA Healthcare Pvt. Ltd.571
  Arena Pharmaceuticals, Inc.581
  Astellas Pharma Inc.591
  BioLingus AG601
  Bionovis SA611
  BioTherapeutics Inc.621
  Calypso Biotech SA631
  Celgene Corporation641
  ChemoCentryx, Inc.651
  ChironWells GmbH661
  CLL Pharma671
  Coherus BioSciences, Inc.681
  Commence Bio, Inc.691
  Daiichi Sankyo Company, Limited701
  DBV Technologies S.A.711
  Eisai Co., Ltd.721
  Eli Lilly and Company731
  Enterome Bioscience SA741
  Enzo Biochem, Inc.751
  Epirus Biopharmaceuticals, Inc.761
  Ferring International Center S.A.771
  Galapagos NV781
  Genentech, Inc.791
  Genor BioPharma Co., Ltd.801
  Gilead Sciences, Inc.811
  iCo Therapeutics Inc.821
  Idera Pharmaceuticals, Inc.831
  Immune Response BioPharma, Inc.841
  Innovent Biologics, Inc.851
  Johnson &Johnson861
  Jyant Technologies, Inc.871
  Kang Stem Biotech Co., Ltd.881
  KPI Therapeutics, Inc.891
  Kyorin Pharmaceutical Co., Ltd.901
  MedImmune, LLC911
  Merck &Co., Inc.921
  Mesoblast Limited931
  Mitsubishi Tanabe Pharma Corporation941
  Momenta Pharmaceuticals, Inc.951
  Mycenax Biotech Inc.961
  Neovacs SA971
  Oncobiologics, Inc.981
  Oncodesign SA991
  OSE Immunotherapeutics1001
  Pfenex Inc.1011
  Pfizer Inc.1021
  Pieris Pharmaceuticals, Inc.1031
  Pluristem Therapeutics Inc.1041
  Protalix BioTherapeutics, Inc.1051
  Qu Biologics Inc.1061
  Re-Pharm Limited1071
  RedHill Biopharma Ltd.1081
  Sandoz International GmbH1091
  SATT North SAS1101
  Second Genome, Inc.1111
  Selexys Pharmaceuticals Corporation1121
  Selvita S.A.1131
  Shire Plc1141
  Sigmoid Pharma Limited1151
  Soligenix, Inc.1161
  Stelic Institute &Co., Inc.1171
  Sylentis S.A.U.1181
  TaiwanJ Pharmaceuticals Co., Ltd.1191
  Takeda Pharmaceutical Company Limited1201
  Therapeutic Proteins International, LLC1211
  Tiziana Life Sciences Plc1221
  Trino Therapeutics Limited1231
  TxCell SA1241
  Ventria Bioscience1251
  Virobay Inc.1261
  Xbrane Biopharma AB1271
Crohn's Disease (Regional Enteritis) Therapeutics Assessment12823
  Assessment by Monotherapy Products1281
  Assessment by Combination Products1291
  Assessment by Target1308
  Assessment by Mechanism of Action1389
  Assessment by Route of Administration1472
  Assessment by Molecule Type1492
Drug Profiles151264
  (clarithromycin + clofazimine + rifabutin) Drug Profile1517
  ABS-11 Drug Profile1581
  adalimumab Drug Profile1598
  adalimumab biosimilar Drug Profile1672
  adalimumab biosimilar Drug Profile1692
  adalimumab biosimilar Drug Profile1711
  adalimumab biosimilar Drug Profile1721
  adalimumab biosimilar Drug Profile1731
  adalimumab biosimilar Drug Profile1741
  adalimumab biosimilar Drug Profile1753
  adalimumab biosimilar Drug Profile1781
  adalimumab biosimilar Drug Profile1791
  adalimumab biosimilar Drug Profile1802
  adalimumab biosimilar Drug Profile1822
  adalimumab biosimilar Drug Profile1841
  adalimumab biosimilar Drug Profile1851
  adalimumab biosimilar Drug Profile1861
  adalimumab biosimilar Drug Profile1871
  Alequel Drug Profile1881
  ALLO-ASC Drug Profile1891
  amiselimod hydrochloride Drug Profile1902
  Ampion Drug Profile1928
  Antisense RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders Drug Profile2001
  ARABS-8 Drug Profile2011
  ATAF-11 Drug Profile2021
  bertilimumab Drug Profile2034
  Biologic for Ulcerative Colitis and Crohn's Disease Drug Profile2071
  brazikumab Drug Profile2082
  BT-11 Drug Profile2102
  CALY-001 Drug Profile2121
  CCX-507 Drug Profile2131
  Cellular Immunotherapy for Crohn s Disease Drug Profile2141
  certolizumab pegol biosimilar Drug Profile2151
  certolizumab pegol biosimilar Drug Profile2161
  CMB-200 Drug Profile2171
  cyclosporine Drug Profile2181
  Drug for Crohn's Disease Drug Profile2191
  Drug to Inhibit Calpain-2 for Crohn's Diseases and Ulcerative Colitis Drug Profile2201
  E-6011 Drug Profile2212
  EB-110 Drug Profile2231
  EB-8018 Drug Profile2241
  EGS-21 Drug Profile2251
  etanercept biosimilar Drug Profile2262
  etrasimod Drug Profile2282
  etrolizumab Drug Profile2302
  ETX-201 Drug Profile2321
  FE-999301 Drug Profile2331
  FFP-102 Drug Profile2341
  FFP-104 Drug Profile2351
  filgotinib Drug Profile2369
  foralumab Drug Profile2451
  Furestem-CD Drug Profile2461
  GLPG-1205 Drug Profile2472
  GS-5745 Drug Profile2492
  IK-003 Drug Profile2511
  IK-004 Drug Profile2521
  IMO-9200 Drug Profile2532
  infliximab Drug Profile2554
  infliximab biosimilar Drug Profile2591
  infliximab biosimilar Drug Profile2601
  infliximab biosimilar Drug Profile2613
  infliximab biosimilar Drug Profile2641
  infliximab biosimilar Drug Profile2651
  infliximab biosimilar Drug Profile2663
  infliximab biosimilar Drug Profile2691
  infliximab biosimilar Drug Profile2701
  INV-88 Drug Profile2711
  IR-777 Drug Profile2721
  JNJ-40346527 Drug Profile2731
  JT-07 Drug Profile2741
  KRP-203 Drug Profile2752
  LY-3074828 Drug Profile2771
  masitinib Drug Profile27814
  molgramostim Drug Profile2921
  mongersen sodium Drug Profile2932
  Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease Drug Profile2951
  Monoclonal Antibodies to Inhibit MMP-2 and MMP-9 for Immunology and Gastrointestinal Disorders Drug Profile2961
  Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis Drug Profile2971
  Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Respiratory Infections Drug Profile2981
  MP-196 Drug Profile2991
  naltrexone hydrochloride Drug Profile3002
  naltrexone hydrochloride Drug Profile3023
  naltrexone hydrochloride Drug Profile3051
  NRG-4 Drug Profile3061
  Ova-Treg Drug Profile3074
  ozanimod hydrochloride Drug Profile3116
  PAC-GI Drug Profile3171
  Peptides to Activate CEACAM5 for Crohn's Disease Drug Profile3181
  PF-04236921 Drug Profile3192
  PF-06480605 Drug Profile3211
  PF-06651600 Drug Profile3221
  PH-44 Drug Profile3231
  PH-46A Drug Profile3241
  PH-5 Drug Profile3251
  PRS-190 Drug Profile3261
  PTG-200 Drug Profile3271
  QBECO-SSI Drug Profile3284
  Recombinant Protein for Crohn's Disease Drug Profile3321
  Recombinant Protein for Crohn s Disease and Ulcerative Colitis Drug Profile3331
  Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis Drug Profile3341
  remestemcel-L Drug Profile3356
  rifaximin Drug Profile3414
  rifaximin DR Drug Profile3451
  risankizumab Drug Profile3463
  RP-0217 Drug Profile3491
  SEL-212 Drug Profile3501
  SelK-2 Drug Profile3511
  SGM-1019 Drug Profile3521
  SGX-203 Drug Profile3532
  SHP-647 Drug Profile3552
  Small Molecule for Crohn s Disease Drug Profile3571
  Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease Drug Profile3581
  Small Molecule to Agonize Mu Opioid Receptor for Crohn's Disease and Ulcerative Colitis Drug Profile3591
  Small Molecules for Crohn s Disease and Ulcerative Colitis Drug Profile3601
  Small Molecules to Antagonize CCR9 for Crohn's Disease and Ulcerative Colitis Drug Profile3611
  Small Molecules to Antagonize Integrin Alpha 4 and Integrin Beta 7 for Inflammatory Diseases Drug Profile3621
  Small Molecules to Inhibit FimH for Urinary Tract Infections and Crohn s Disease Drug Profile3631
  Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis Drug Profile3641
  SQ-641 Drug Profile3651
  Stem Cell Therapy for Autoimmune Diseases Drug Profile3662
  Stem Cell Therapy for Inflammatory Bowel Disease Drug Profile3682
  STNM-01 Drug Profile3701
  SYN-1002 Drug Profile3711
  Synthetic Peptides To Inhibit Interleukin-6 for Crohn's Disease and Rheumatoid Arthritis Drug Profile3721
  TAK-828 Drug Profile3731
  teduglutide Drug Profile3746
  Thetanix Drug Profile3801
  U-2902 Drug Profile3812
  upadacitinib tartrate Drug Profile3832
  ustekinumab Drug Profile3856
  Vaccine to Target TNF Alpha for Crohn's Disease, Rheumatoid Arthritis and Psoriasis Drug Profile3914
  VBY-036 Drug Profile3952
  VBY-129 Drug Profile3971
  vedolizumab Drug Profile3985
  VEN-100 Drug Profile4032
  VEN-120 Drug Profile4051
  vercirnon sodium Drug Profile4063
  vidofludimus Drug Profile4094
  zucapsaicin Drug Profile4132
Crohn's Disease (Regional Enteritis) Dormant Projects41512
Crohn's Disease (Regional Enteritis) Discontinued Products4272
Crohn's Disease (Regional Enteritis) Product Development Milestones42912
  Featured News &Press Releases4291
    Jul 17, 2016: SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency4291

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Crohn-s-Disease-Regional-Enteritis-Pipeline-Review-H2-2016-2088-16362>
  
APA:
Global Markets Direct - Market Research. (2016). Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Crohn-s-Disease-Regional-Enteritis-Pipeline-Review-H2-2016-2088-16362>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.